While Reising client Cerephex® has been working through the final stages of obtaining FDA clearance to market their revolutionary NeuroPoint® product for the remediation of Fibromyalgia and other brain-related disorders, Reising Ethington continues to seek and successfully obtain intellectual property protection for Cerephex products and trade names. Recently, Reising attorney Eric Jones travelled with Cerephex® Chief Scientific Officer Jeff Hargrove to the United States Patent Office (USPTO) in Washington D.C. to meet with USPTO officials over a patent examiner’s refusal to allow claims broader than those of Cerephex’s currently issued patents, which cover the use of a specific type of electrical signal to diagnose and treat brain-related disorders. After lengthy negotiations, Jones and Hargrove were able to convince the USPTO to allow claims broad enough to cover the use of any electrical signal that has separate treatment and tissue penetration components. As a result, Cerephex’s third US patent issued on July 23, 2013 as US Patent 8,494,625. Once NeuroPoint is FDA approved, Cerephex® will work with physicians and caregivers worldwide to make the patented NeuroPoint® neuromodulation therapy available, and continue their mission to provide high quality clinical solutions for chronic pain. A final FDA clinical trial is scheduled to take place in early 2014 at multiple sites throughout the United States. For anyone interested in enrolling, please check www.cerephex.com/Patients.html for details as they become available.
